Anticipated $-0.14 EPS for OncoSec Medical Incorporated (ONCS) on June, 7

May 17, 2018 - By Clyde Turner

OncoSec Medical Incorporated (NASDAQ:ONCS) Corporate Logo

On June, 7. Investors wait OncoSec Medical Incorporated (NASDAQ:ONCS) to publish its quarterly earnings, as reported by RTT. This year’s EPS analyst estimate is anticipated to be $-0.14. That is 36.36 % up compareed to $-0.22 EPS for last year. Wall Street sees -41.67 % EPS growth as of June, 7. Ticker’s shares touched $1.78 during the last trading session after 4.09% change.OncoSec Medical Incorporated has 1.54M shares volume, 30.90% up from normal. ONCS is uptrending and has moved 44.62% since May 17, 2017. The stock outperformed the S&P500 by 33.07%.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States.The firm is worth $91.64 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer.Last it reported negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

Another two news for OncoSec Medical Incorporated (NASDAQ:ONCS) were recently announced by: on May 08, 2018 with title “Oncosec Medical (ONCS) Expands Relationship with Merck (MRK); Announces Clinical Collaboration to Evaluate …”. The other‘s article was titled “OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner” and announced on April 18, 2018.

OncoSec Medical Incorporated (NASDAQ:ONCS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.